SEC Form SC 13G/A filed by Generation Bio Co. (Amendment)

$GBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $GBIO alert in real time by email
SC 13G/A 1 d780097dsc13ga.htm SC 13G/A SC 13G/A

 

 

United States

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

 

 

Generation Bio Co.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

37148K100

(CUSIP Number)

December 31, 2023

(Date of Event Which Requires Filing This Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 37148K100

 

 1.   

 Names of Reporting Persons

 

BB Biotech AG

 2.  

 Check the Appropriate Box if a Member of a Group (See Instructions)

 (a) ☒  (b) ☐

 

 3.  

 SEC Use Only

 

 4.  

 Citizenship or Place of Organization

 

Switzerland

Number of

Shares  Beneficially 

Owned by

Each

Reporting

Person

with:

   5.   

 Sole Voting Power

 

0

   6.  

 Shared Voting Power

 

3,608,280

   7.  

 Sole Dispositive Power

 

0

   8.  

 Shared Dispositive Power

 

3,608,280

 9.   

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

3,608,280

10.  

 Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

 ☐

11.  

 Percent of Class Represented by amount in Row (9)

 

5.5%

12.  

 Type of Reporting Person (See Instructions)

 

HC, CO

2 of 6


CUSIP No. 37148K100

 

 1.   

 Names of Reporting Persons

 

Biotech Growth N.V.

 2.  

 Check the Appropriate Box if a Member of a Group (See Instructions)

 (a) ☒  (b) ☐

 

 3.  

 SEC Use Only

 

 4.  

 Citizenship or Place of Organization

 

Curaçao

Number of

Shares  Beneficially 

Owned by

Each

Reporting

Person

with:

   5.   

 Sole Voting Power

 

0

   6.  

 Shared Voting Power

 

3,608,280

   7.  

 Sole Dispositive Power

 

0

   8.  

 Shared Dispositive Power

 

3,608,280

 9.   

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

3,608,280

10.  

 Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

 ☐

11.  

 Percent of Class Represented by amount in Row (9)

 

5.5%

12.  

 Type of Reporting Person (See Instructions)

 

CO

3 of 6


Item 1

1(a) Name of Issuer: Generation Bio Co.

1(b) Address of Issuer’s Principal Executive Offices:

301 Binney Street, Cambridge, MA 02142, United States

Item 2

2(a) Name of Person Filing: BB Biotech AG (“BB Biotech”) on behalf of its wholly-owned subsidiary, Biotech Growth N.V. (“Biotech Growth”)

2(b) Address of Principal Business Office or, if none, Residence:

BB Biotech AG: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland

Biotech Growth N.V.: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curaçao

2(c) Citizenship:    BB Biotech AG: Switzerland

Biotech Growth N.V.: Curaçao

2(d) Title of Class of Securities: Common Stock, $0.0001 par value

2(e) CUSIP Number: 37148K100

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned: 3,608,280

(b) Percent of class: 5.5%

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote 0

(ii) Shared power to vote or to direct the vote 3,608,280

(iii) Sole power to dispose or to direct the disposition of 0

(iv) Shared power to dispose or to direct the disposition of 3,608,280

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

This statement is filed jointly by BB Biotech and Biotech Growth, Biotech Growth is a wholly-owned subsidiary of BB Biotech.

 

4 of 6


Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BB Biotech AG

 

Date: February 6, 2024     By:  

/s/ Martin Gubler

      Signatory Authority
    Name:   Martin Gubler
    Title:   Signatory Authority
Date: February 6, 2024     By:  

/s/ Ivo Betschart

      Signatory Authority
    Name:   Ivo Betschart
    Title:   Signatory Authority
Biotech Growth N.V.      
Date: February 6, 2024     By:  

/s/ Jan Bootsma

      Signatory Authority
    Name:   Jan Bootsma
    Title:   Signatory Authority
Date: February 6, 2024     By:  

/s/ Hugo van Neutegem

      Signatory Authority
    Name:   Hugo van Neutegem
    Title:   Signatory Authority

 

5 of 6


Exhibit Index

Exhibit A: Agreement by and between BB Biotech AG and Biotech Growth N.V. with respect to the filing of this disclosure statement.*

 

 

*

Previously filed as an exhibit to BB Biotech AG and Biotech Growth N.V.’s Schedule 13G filed with the Securities and Exchange Commission on January 8, 2021.

 

6 of 6

Get the next $GBIO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GBIO

DatePrice TargetRatingAnalyst
10/19/2023Outperform → Market Perform
TD Cowen
11/8/2022$9.00Buy
Canaccord Genuity
12/15/2021$40.00 → $10.00Market Outperform
JMP Securities
12/15/2021$50.00 → $27.00Buy
Needham
12/14/2021Outperform → Mkt Perform
William Blair
More analyst ratings

$GBIO
Press Releases

Fastest customizable press release news feed in the world

See more
  • Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

    -  Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases -  Lead target and indication to be announced MY 2025 -  Cash balance of $185.2 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., March 13, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, reported business highlights and fourth quarter and full year 2024 financial results. "Our T cell-selective lipid nanoparticle (LNP) is designed to overcome a

    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference

    CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:10 a.m. ET in Boston. A live webcast of the presentation will be available on the investor section of the company's website at investors.generationbio.com. A replay will be available there for 30 days following the event.   About Generation Bio    Generation Bio is a biotechnology company changing what's possible for peo

    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.

    Tubulis today announced the appointment of Matthew Norkunas, MD, MBA, as Chief Financial Officer (CFO) and President of Tubulis Inc., further strengthening its management team at a pivotal stage of growth. Dr. Norkunas' proven track record of achieving financial and corporate goals for rapidly evolving biotechs will be instrumental in advancing Tubulis' strategic objectives. His unique background as a physician-turned-business executive will support the company's position as a leader and innovator in ADC drug development. Based in Tubulis' U.S. Cambridge office, Dr. Norkunas' appointment also expands the company's U.S. presence. "Tubulis has built a strong financial position to advance it

    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GBIO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$GBIO
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$GBIO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$GBIO
SEC Filings

See more

$GBIO
Leadership Updates

Live Leadership Updates

See more
  • Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.

    Tubulis today announced the appointment of Matthew Norkunas, MD, MBA, as Chief Financial Officer (CFO) and President of Tubulis Inc., further strengthening its management team at a pivotal stage of growth. Dr. Norkunas' proven track record of achieving financial and corporate goals for rapidly evolving biotechs will be instrumental in advancing Tubulis' strategic objectives. His unique background as a physician-turned-business executive will support the company's position as a leader and innovator in ADC drug development. Based in Tubulis' U.S. Cambridge office, Dr. Norkunas' appointment also expands the company's U.S. presence. "Tubulis has built a strong financial position to advance it

    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results

    Company entered into strategic collaboration with Moderna to use Generation Bio's proprietary non-viral genetic medicine delivery system for two liver disease programs and to co-develop novel targeting for immune cells Factor VIII expression data in non-human primates for wholly-owned hemophilia A program expected in 2023 First quarter 2023 cash balance of $288.6 million expected to fund operations into 2025; additional $47.5 million from Moderna collaboration received in second quarter 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent disea

    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Generation Bio Appoints Yalonda Howze, J.D. as Chief Legal Officer

    CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Yalonda Howze, J.D. has been appointed chief legal officer and secretary. "We are delighted to welcome Yalonda to the Generation Bio leadership team and look forward to drawing on her extensive legal expertise as we continue to execute on our vision of reaching the full potential of genetic medicine," said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. "Generation Bio is pursuing an ambitious goal to develop lifelong, titratable gain of function DNA th

    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GBIO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more